Orchard Therapeutics appoints Mark Rothera as CEO
Gene therapy specialist Orchard Therapeutics (London) has appointed Mark Rothera as President and Chief Executive Officer, a specialist for the commercialisation of novel treatments and business development.
In his 28 year-career in the biopharma industry, Rothera has focused on commercialisation of orphan drug programmes. Before joining Orchard, Rothera served as Chief Commercial Officer of PTC Therapeutics. Prior to joining PTC, he served as Global President of Aegerion Pharmaceuticals Inc. and Vice President and General Manager of commercial operations at Shire Human Genetic Therapies for Europe, Middle East and Africa. Rothera received an M.A. in Natural Sciences from Cambridge University and an MBA from INSEAD.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium